Phenotypic Heterogeneity of Hemostasis in Severe Hemophilia

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 8, 2015, Pages 826-831

  Nogami, Keiji ^a   Shima, Midori ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

clinical phenotype; heterogeneity; severe hemophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; DRUG HALF LIFE; ENVIRONMENTAL FACTOR; HEMOPHILIA; HEMOSTASIS; HUMAN; INDEL MUTATION; INTRON; LIFESTYLE; NONSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; GENETICS; HEMOPHILIA A;

HEMOPHILIA A; HEMOSTASIS; HUMANS; PHENOTYPE;

EID: 84946730452     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1395349     Document Type: Article

References (49)

1. White G. C. II, Rosendaal F.; Aledort L. M.; Lusher J. M.; Rothschild C.; Ingerslev J.; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost: 2001; 85 3 560
2. Schramm W.; Royal S.; Kroner B.; et al. European haemophilia economic study group. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia: 2002; 8 1 33 43
3. Molho P.; Rolland N.; Lebrun T.; et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr. Haemophilia: 2000; 6 1 23 32
4. Bolton-Maggs P. H.; Pasi K. J. Haemophilias A and B. Lancet: 2003; 361 9371 1801 1809
5. Aledort L. M.; Haschmeyer R. H.; Pettersson H.; The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med: 1994; 236 4 391 399
6. Jayandharan G. R.; Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost: 2008; 34 1 128 141
7. van den Berg H. M.; De Groot P. H.; Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost: 2007; 5 01 151 156
8. Hemker H. C.; Giesen P.; Al Dieri R.; et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb: 2003; 33 1 4 15
9. Shima M.; Matsumoto T.; Fukuda K.; et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost: 2002; 87 3 436 441
10. Onwuzurike N.; Warrier I.; Lusher J. M. Types of bleeding seen during the first 30 months of life in children with severe haemophilia A and B. Haemophilia: 1996; 2 137 140
11. van Dijk K.; Fischer K.; van der Bom J. G.; Grobbee D. E.; van den Berg H. M. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia: 2005; 11 5 438 443
12. Plug I.; van der Bom J. G.; Peters M.; et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood: 2004; 104 12 3494 3500
13. Ljung R.; Petrini P.; Nilsson I. M. Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases. Acta Paediatr Scand: 1990; 79 2 196 200
14. Fischer K.; van der Bom J. G.; Mauser-Bunschoten E. P.; et al. Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia. Thromb Haemost: 2000; 84 6 977 980
15. Rainsford S. G.; Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol: 1973; 24 5 539 551
16. Bertina R. M.; Koeleman B. P.; Koster T.; et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature: 1994; 369 6475 64 67
17. Escuriola Ettingshausen C.; Halimeh S.; Kurnik K.; et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost: 2001; 85 2 218 220
18. Nichols W. C.; Amano K.; Cacheris P. M.; et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood: 1996; 88 4 1183 1187
19. Nowak-Göttl U.; Escuriola C.; Kurnik K.; et al. Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations? Hamostaseologie: 2003; 23 1 36 40
20. Lee D. H.; Walker I. R.; Teitel J.; et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost: 2000; 83 3 387 391
21. Grünewald M.; Siegemund A.; Grünewald A.; Konegan A.; Koksch M.; Griesshammer M. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia: 2002; 8 6 768 775
22. van Dijk K.; van der Bom J. G.; Fischer K.; de Groot P. G.; van den Berg H. M. Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis. J Thromb Haemost: 2007; 5 5 1062 1064
23. Jayandharan G. R.; Nair S. C.; Poonnoose P. M.; et al. Polymorphism in factor VII gene modifies phenotype of severe haemophilia. Haemophilia: 2009; 15 6 1228 1236
24. Foley J. H.; Nesheim M. E.; Rivard G. E.; Brummel-Ziedins K. E. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A. Haemophilia: 2012; 18 3 e316 e322
25. Mosnier L. O.; Lisman T.; van den Berg H. M.; Nieuwenhuis H. K.; Meijers J. C.; Bouma B. N. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost: 2001; 86 4 1035 1039
26. Oldenburg J. Mutation profiling in haemophilia A. Thromb Haemost: 2001; 85 4 577 579
27. Jayandharan G.; Shaji R. V.; Baidya S.; Nair S. C.; Chandy M.; Srivastava A. Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions. Haemophilia: 2005; 11 5 481 491
28. Jayandharan G. R.; Shaji R. V.; Baidya S.; Nair S. C.; Chandy M.; Srivastava A. Molecular characterization of factor IX gene mutations in 53 patients with haemophilia B in India. Thromb Haemost: 2005; 94 4 883 886
29. Goodeve A. C.; Preston F. E.; Peake I. R. Factor VIII gene rearrangements in patients with severe haemophilia A. Lancet: 1994; 343 8893 329 330
30. Bertina R. M. Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb: 2003; 33 5-6 395 400
31. Iacoviello L.; Di Castelnuovo A.; De Knijff P.; et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med: 1998; 338 2 79 85
32. Frère C.; Morange P. E.; Saut N.; et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost: 2005; 94 2 373 379
33. Frosst P.; Blom H. J.; Milos R.; et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet: 1995; 10 1 111 113
34. Fijnvandraat K.; Peters M.; ten Cate J. W. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol: 1995; 91 2 474 476
35. Vlot A. J.; Mauser-Bunschoten E. P.; Zarkova A. G.; et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost: 2000; 83 1 65 69
36. van Dijk K.; van der Bom J. G.; Lenting P. J.; et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica: 2005; 90 4 494 498
37. Hilberg T.; Herbsleb M.; Puta C.; Gabriel H. H.; Schramm W. Physical training increases isometric muscular strength and proprioceptive performance in haemophilic subjects. Haemophilia: 2003; 9 1 86 93
38. Harris S.; Boggio L. N. Exercise may decrease further destruction in the adult haemophilic joint. Haemophilia: 2006; 12 3 237 240
39. Czepa D.; von Mackensen S.; Hilberg T. Haemophilia & Exercise Project (HEP): the impact of 1-year sports therapy programme on physical performance in adult haemophilia patients. Haemophilia: 2013; 19 2 194 199
40. Barnes C.; Blanchette V.; Lillicrap D.; et al. Different clinical phenotype in triplets with haemophilia A. Haemophilia: 2007; 13 2 202 205
41. Verhoef C. M.; van Roon J. A.; Vianen M. E.; Bijlsma J. W.; Lafeber F. P. Interleukin 10 (IL-10), not IL-4 or interferon-gamma production, correlates with progression of joint destruction in rheumatoid arthritis. J Rheumatol: 2001; 28 9 1960 1966
42. Matsumoto T.; Shima M.; Takeyama M.; et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost: 2006; 4 2 377 384
43. Shima M.; Matsumoto T.; Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia: 2008; 14 03 83 92
44. Trossaërt M.; Regnault V.; Sigaud M.; Boisseau P.; Fressinaud E.; Lecompte T. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost: 2008; 6 3 486 493
45. Santagostino E.; Mancuso M. E.; Tripodi A.; et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost: 2010; 8 4 737 743
46. Gilmore R.; Harmon S.; Gannon C.; Byrne M.; O'Donnell J. S.; Jenkins P. V. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy. Haemophilia: 2010; 16 4 671 674
47. Dargaud Y.; Béguin S.; Lienhart A.; et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost: 2005; 93 3 475 480
48. Matsumoto T.; Nogami K.; Ogiwara K.; Shima M. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol: 2009; 90 5 576 582
49. Yada K.; Nogami K.; Wakabayashi H.; Fay P. J.; Shima M. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X. Thromb Haemost: 2013; 109 6 1007 1015